一种敏感的ALK免疫组化伴随诊断检测可识别适合接受克唑替尼治疗的患者
研究在PROFILE 1014试验中对1018例NSCLC标本(包括179例ALK阳性和754例ALK阴性)用Ventana ALK(D5F3)CDx检测评估,与FISH一致性总体94.3%,ALK IHC阳性与FISH阳性患者克唑替尼对比化疗的无进展生存期风险比分别为0.401和0.407。
要点
- ALK(D5F3)CDx检测与FISH的阳性、阴性及总体一致率分别为86.0%、96.3%和94.3%。
- ALK IHC阳性患者克唑替尼对比化疗的无进展生存期风险比为0.401。
- 三间独立实验室间ALK IHC的判读者间一致率超过98%。
核心结论
- ALK(D5F3)CDx检测是用于识别适合接受克唑替尼治疗患者的独立伴随诊断检测。
- 该自动化检测为准确快速识别ALK阳性NSCLC患者提供了有效选择。
- 简单的二元评分算法带来高的判读者间精密度。
研究设计与样本
- 研究对PROFILE 1014临床试验(克唑替尼对比化疗,N=1018,包括179例ALK阳性和754例ALK阴性标本)中前瞻性经FISH检测ALK状态的NSCLC标本,使用ALK(D5F3)CDx检测进行评估。
- 研究比较了ALK IHC阳性患者与ALK FISH阳性患者中克唑替尼对比化疗的无进展生存期风险比,以及与入组时ALK FISH检测的一致性。
主要发现
- 两种检测均获得结果的病例为933例。
- 阳性、阴性和总体一致率分别为86.0%、96.3%和94.3%。
- 不一致病例53例,其中25例为ALK FISH阳性/ALK IHC阴性,28例为ALK FISH阴性/ALK IHC阳性。
- 采用观察结局的风险比:ALK FISH阳性/ALK IHC阳性病例为0.401,经ALK IHC检测的所有ALK FISH阳性病例为0.407,而试验中入组的所有ALK FISH阳性病例为0.454。
- ALK FISH阴性/ALK IHC阳性病例的结局数据不可用于分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- ALK FISH阴性/ALK IHC阳性病例的结局数据不可用于分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The availability of high-quality, rigorously validated diagnostic tests that can be broadly implemented is necessary to efficiently identify patients with anaplastic lymphoma kinase (ALK)-positive NSCLC who can potentially benefit from treatment with crizotinib. Here we present data on the recently approved Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ), the only immunohistochemistry (IHC)-based assay linked to treatment outcome. METHODS: NSCLC specimens prospectively tested for anaplastic lymphoma receptor tyrosine kinase gene (ALK) status by flourescent in situ hybridization (FISH) in the PROFILE 1014 clinical trial of crizotinib versus chemotherapy (N = 1018, including 179 ALK-positive and 754 ALK-negative specimens) were evaluated using the ALK (D5F3) CDx assay. Hazard ratios for progression-free survival comparing crizotinib and chemotherapy for ALK IHC-positive patients and ALK FISH-positive patients, as well as for concordance with the enrollment ALK FISH assay, were determined. RESULTS: Results from both assays were obtained for 933 cases. Percent positive, negative, and overall agreement rates were 86.0% , 96.3%, and 94.3%, respectively. There were 53 discrepant cases, of which 25 were ALK FISH-positive/ALK IHC-negative and 28 were ALK FISH-negative/ALK IHC-positive. The hazard ratios using observed outcomes were 0.401 for ALK FISH-positive/ALK IHC-positive cases and 0.407 for all ALK FISH-positive cases tested with ALK IHC versus 0.454 for all ALK FISH-positive cases enrolled in the trial. Outcome data for ALK FISH-negative/ALK IHC-positive cases were not available for analysis. Between-reader agreement rates for ALK IHC involving three independent laboratories exceeded 98%. CONCLUSIONS: The ALK (D5F3) CDx assay is a stand-alone companion diagnostic test for identification of patients for treatment with crizotinib. This automated assay provides an effective option to accurately and rapidly identify patients with ALK-positive NSCLC. The simple binary scoring algorithm results in high reader-to-reader precision.
引用
- Thorne-Nuzzo T, Williams C, Catallini A, et al. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol. 2017. PMID: 28147239. doi:10.1016/j.jtho.2017.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。